ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Analyzing Effects of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression

by Amy E. Hamaker • December 9, 2019

  • Tweet
  • Email
Print-Friendly Version

You Might Also Like

No related posts.

Explore This Issue
December 2019

Comment: This article highlights an issue that I am working to become more familiar with: nasal medication and interventions NOT typically prescribed by otolaryngologists, but that we may get asked about because we are the assumed experts on all things nasal! This nasal spray is just one example. There are also nasal cooling devices being investigated for the treatment of stroke and traumatic brain injury (available at: ahajournals.org/doi/full/10.1161/STROKEAHA.110.613000 and braincool.se/en/home-2/). If they are widely adopted, it behooves us to at least have a working familiarity with these interventions. —Jennifer A. Villwock, MD

What are the long-term effects of esketamine nasal spray in patients with treatment-resistant depression (TRD)?

Bottom line: For patients with TRD who experienced remission or response after esketamine treatment, continuation of esketamine nasal spray in addition to oral antidepressant treatment resulted in clinically meaningful superiority in delaying relapse compared with antidepressant plus placebo.

Background: Depression is the leading cause of disability worldwide and is associated with a 10-year reduction in life expectancy. Patients with treatment-resistant major depressive disorder (MDD) experience relapse at a higher rate than do those with treatment-responsive MDD. In contrast to available data about short-term antidepressant effects of esketamine and ketamine, little is known about maintaining long-term antidepressant effects.

Study design: A multicenter, double-blind, randomized withdrawal study of 297 adults with prospectively confirmed TRD was conducted from Oct. 6, 2015, to Feb. 15, 2018.

Setting: A variety of academic and nonacademic clinic settings across the United States, Canada, and Europe.

Synopsis: Overall, among patients who achieved stable remission, 24 in the esketamine/antidepressant group and 39 in the antidepressant/placebo group experienced a relapse event during the maintenance phase; among patients who achieved a stable response (but not remission), 16 in the esketamine/antidepressant group and 34 in the antidepressant/placebo group experienced relapse. Continued treatment with esketamine and antidepressant significantly delayed and decreased relapse compared with treatment with antidepressant and placebo. The five most common adverse effects (AEs) reported in the esketamine/antidepressant group were dysgeusia, vertigo, dissociation, somnolence, and dizziness. Most AEs were mild to moderate, observed after dosing, and generally resolved in the same day. No deaths were reported. Serious AEs were reported for six esketamine/antidepressant patients (autonomic nervous system imbalance, disorientation, hypothermia, lacunar stroke, sedation, simple partial seizures, and suicidal ideation) during the induction phase. Transient blood pressure increases were observed with esketamine on treatment days and typically returned to the predose range by 1.5 hours after administration. Limitations included the fact that esketamine has known transient dissociative and sedative effects that are difficult to blind.

Citation: Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. A randomized clinical trial. JAMA Psychiatry. 2019;76:893–903.

Pages: 1 2 | Single Page

Filed Under: Literature Reviews, Rhinology Tagged With: depression, nasal spray, treatmentIssue: December 2019

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Complications for When Physicians Change a Maiden Name
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Otolaryngologists Elected to AMA Board of Trustees
    • FDA Approves First Treatment for Eosinophilic Esophagitis
    • Clinical Best Practices: Otolaryngologists Tackle Questions
    • Otolaryngologist Shares Experience with Image Manipulation in Research and How to Prevent It
    • Methodology to Study Care Barriers for Head and Neck Cancer Patients in Low- and Middle-Income Countries Yields Insights

Polls

Do you think most image manipulation in studies is done accidentally or on purpose?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2022 The Triological Society. All Rights Reserved.
ISSN 1559-4939